Effect of methotrexate on pulmonary involvement in patients with rheumatoid arthritis
Identifieur interne : 001F96 ( Main/Exploration ); précédent : 001F95; suivant : 001F97Effect of methotrexate on pulmonary involvement in patients with rheumatoid arthritis
Auteurs : Tas Gökhan ; Özoran Kürsat [Niger] ; Ak Gülseren ; Bostanoglu Sevinç ; Arikan Serpil [Turquie] ; Mermerci BedriyeSource :
- APLAR Journal of Rheumatology [ 0219-0494 ] ; 2004-05.
English descriptors
- Teeft :
- Adverse effects, Alkaline phosphatase, Aplar journal, Arterial blood gases, Arthritis, Arthritis rheum, Autopsy series, Brosis, Chloroquine, Chloroquine group, Chloroquine phosphate, Chloroquine therapy, Disease duration, Distinct conclusions, Erythrocyte sedimentation rate, Female patients, Fev1, High resolution, Hrct, Hrct scan signs, Hrct scans, Independent evaluation, Initial values, Interstitial, Interstitial lung disease, Involvement ratios, Laboratory parameters, Laboratory values, Limited number, Lung disease, Lung involvement, Lung pathologies, Male patients, Methotrexate, Months disease duration, Nodule, Partial pressure, Patient group, Pleural effusion, Pleural involvement, Pulmonary function tests, Pulmonary involvement, Pulmonary nodules, Pulmonary oedema, Radiological, Radiological progression, Rheumatoid, Rheumatoid arthritis, Rheumatoid factor, Rheumatol, Rheumatology, Risk factors, Routine laboratory investigations, Second group, Second line therapy, Sixth month, Statistical analyses, Statistical analysis, Tomography, Treatment years, Vital capacity.
Abstract
Objective: The aim of this study is to determine the effects of methotrexate (MTX) therapy on pulmonary involvement in patients with rheumatoid arthritis (RA). Method: Fifty‐five non‐smoking RA patients were included in the study. Routine laboratory investigations, pulmonary function tests (PFT), high resolution computed tomography (HRCT) and arterial blood gas analysis were performed in all of the patients. Randomly dividing the patients into two groups, the first group were given 7.5 mg/week MTX and the second group were given 250 mg/day chloroquine phosphate. At the end of the sixth month all the tests and the analysis were repeated and evaluated by using χ2 and Student's t‐test; P < 0.05 was considered statistically significant. Results: At the beginning of the study, HRCT examination revealed 92.7% pulmonary involvement in 55 RA patients. At the sixth month although the RA patients in the chloroquine group did not show any difference, RA patients in the MTX group displayed statistically significant increases in their pulmonary involvement (P < 0.05). Patients in the MTX group also displayed significant decreases at FEV1/FVC and significant increases at FEV1 in PFT and O2 saturation (P < 0.05, P < 0.05 and P < 0.01, respectively). In the chloroquine group we observed significant increases in FEV1 and vital capacity (P < 0.05). Conclusion: Although the MTX therapy increases the risk of pulmonary involvement in patients with RA, it also increases the ventilation which in turn increases the functional capacity of the patient. Considering the beneficial effect on the radiological progression of the disease, we think that MTX therapy should be taken into account as the first choice in the treatment of RA.
Url:
DOI: 10.1111/j.1479-8077.2004.00056.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000199
- to stream Istex, to step Curation: 000199
- to stream Istex, to step Checkpoint: 000E37
- to stream Main, to step Merge: 002011
- to stream Main, to step Curation: 001F96
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of methotrexate on pulmonary involvement in patients with rheumatoid arthritis</title><author><name sortKey="Gokhan, Tas" sort="Gokhan, Tas" uniqKey="Gokhan T" first="Tas" last="Gökhan">Tas Gökhan</name></author><author><name sortKey="Kursat, Ozoran" sort="Kursat, Ozoran" uniqKey="Kursat O" first="Özoran" last="Kürsat">Özoran Kürsat</name></author><author><name sortKey="Gulseren, Ak" sort="Gulseren, Ak" uniqKey="Gulseren A" first="Ak" last="Gülseren">Ak Gülseren</name></author><author><name sortKey="Sevinc, Bostanoglu" sort="Sevinc, Bostanoglu" uniqKey="Sevinc B" first="Bostanoglu" last="Sevinç">Bostanoglu Sevinç</name></author><author><name sortKey="Serpil, Arikan" sort="Serpil, Arikan" uniqKey="Serpil A" first="Arikan" last="Serpil">Arikan Serpil</name></author><author><name sortKey="Bedriye, Mermerci" sort="Bedriye, Mermerci" uniqKey="Bedriye M" first="Mermerci" last="Bedriye">Mermerci Bedriye</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F5535857B2197827217518992DAA4B603F3B5298</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1111/j.1479-8077.2004.00056.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-6QCNM4PP-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000199</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000199</idno><idno type="wicri:Area/Istex/Curation">000199</idno><idno type="wicri:Area/Istex/Checkpoint">000E37</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E37</idno><idno type="wicri:doubleKey">0219-0494:2004:Gokhan T:effect:of:methotrexate</idno><idno type="wicri:Area/Main/Merge">002011</idno><idno type="wicri:Area/Main/Curation">001F96</idno><idno type="wicri:Area/Main/Exploration">001F96</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Effect of methotrexate on pulmonary involvement in patients with rheumatoid arthritis</title><author><name sortKey="Gokhan, Tas" sort="Gokhan, Tas" uniqKey="Gokhan T" first="Tas" last="Gökhan">Tas Gökhan</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Kursat, Ozoran" sort="Kursat, Ozoran" uniqKey="Kursat O" first="Özoran" last="Kürsat">Özoran Kürsat</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Niger</country></affiliation></author><author><name sortKey="Gulseren, Ak" sort="Gulseren, Ak" uniqKey="Gulseren A" first="Ak" last="Gülseren">Ak Gülseren</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Sevinc, Bostanoglu" sort="Sevinc, Bostanoglu" uniqKey="Sevinc B" first="Bostanoglu" last="Sevinç">Bostanoglu Sevinç</name><affiliation><wicri:noCountry code="no comma">Radiology and</wicri:noCountry></affiliation></author><author><name sortKey="Serpil, Arikan" sort="Serpil, Arikan" uniqKey="Serpil A" first="Arikan" last="Serpil">Arikan Serpil</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Pulmonary Department, Ankara Numune Education and Research Hospital, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Bedriye, Mermerci" sort="Bedriye, Mermerci" uniqKey="Bedriye M" first="Mermerci" last="Bedriye">Mermerci Bedriye</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">APLAR Journal of Rheumatology</title><title level="j" type="alt">APLAR JOURNAL OF RHEUMATOLOGY</title><idno type="ISSN">0219-0494</idno><idno type="eISSN">1479-8077</idno><imprint><biblScope unit="vol">7</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="24">24</biblScope><biblScope unit="page" to="29">29</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-05">2004-05</date></imprint><idno type="ISSN">0219-0494</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0219-0494</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse effects</term><term>Alkaline phosphatase</term><term>Aplar journal</term><term>Arterial blood gases</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autopsy series</term><term>Brosis</term><term>Chloroquine</term><term>Chloroquine group</term><term>Chloroquine phosphate</term><term>Chloroquine therapy</term><term>Disease duration</term><term>Distinct conclusions</term><term>Erythrocyte sedimentation rate</term><term>Female patients</term><term>Fev1</term><term>High resolution</term><term>Hrct</term><term>Hrct scan signs</term><term>Hrct scans</term><term>Independent evaluation</term><term>Initial values</term><term>Interstitial</term><term>Interstitial lung disease</term><term>Involvement ratios</term><term>Laboratory parameters</term><term>Laboratory values</term><term>Limited number</term><term>Lung disease</term><term>Lung involvement</term><term>Lung pathologies</term><term>Male patients</term><term>Methotrexate</term><term>Months disease duration</term><term>Nodule</term><term>Partial pressure</term><term>Patient group</term><term>Pleural effusion</term><term>Pleural involvement</term><term>Pulmonary function tests</term><term>Pulmonary involvement</term><term>Pulmonary nodules</term><term>Pulmonary oedema</term><term>Radiological</term><term>Radiological progression</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid factor</term><term>Rheumatol</term><term>Rheumatology</term><term>Risk factors</term><term>Routine laboratory investigations</term><term>Second group</term><term>Second line therapy</term><term>Sixth month</term><term>Statistical analyses</term><term>Statistical analysis</term><term>Tomography</term><term>Treatment years</term><term>Vital capacity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: The aim of this study is to determine the effects of methotrexate (MTX) therapy on pulmonary involvement in patients with rheumatoid arthritis (RA). Method: Fifty‐five non‐smoking RA patients were included in the study. Routine laboratory investigations, pulmonary function tests (PFT), high resolution computed tomography (HRCT) and arterial blood gas analysis were performed in all of the patients. Randomly dividing the patients into two groups, the first group were given 7.5 mg/week MTX and the second group were given 250 mg/day chloroquine phosphate. At the end of the sixth month all the tests and the analysis were repeated and evaluated by using χ2 and Student's t‐test; P < 0.05 was considered statistically significant. Results: At the beginning of the study, HRCT examination revealed 92.7% pulmonary involvement in 55 RA patients. At the sixth month although the RA patients in the chloroquine group did not show any difference, RA patients in the MTX group displayed statistically significant increases in their pulmonary involvement (P < 0.05). Patients in the MTX group also displayed significant decreases at FEV1/FVC and significant increases at FEV1 in PFT and O2 saturation (P < 0.05, P < 0.05 and P < 0.01, respectively). In the chloroquine group we observed significant increases in FEV1 and vital capacity (P < 0.05). Conclusion: Although the MTX therapy increases the risk of pulmonary involvement in patients with RA, it also increases the ventilation which in turn increases the functional capacity of the patient. Considering the beneficial effect on the radiological progression of the disease, we think that MTX therapy should be taken into account as the first choice in the treatment of RA.</div></front></TEI><affiliations><list><country><li>Niger</li><li>Turquie</li></country></list><tree><noCountry><name sortKey="Bedriye, Mermerci" sort="Bedriye, Mermerci" uniqKey="Bedriye M" first="Mermerci" last="Bedriye">Mermerci Bedriye</name><name sortKey="Gokhan, Tas" sort="Gokhan, Tas" uniqKey="Gokhan T" first="Tas" last="Gökhan">Tas Gökhan</name><name sortKey="Gulseren, Ak" sort="Gulseren, Ak" uniqKey="Gulseren A" first="Ak" last="Gülseren">Ak Gülseren</name><name sortKey="Sevinc, Bostanoglu" sort="Sevinc, Bostanoglu" uniqKey="Sevinc B" first="Bostanoglu" last="Sevinç">Bostanoglu Sevinç</name></noCountry><country name="Niger"><noRegion><name sortKey="Kursat, Ozoran" sort="Kursat, Ozoran" uniqKey="Kursat O" first="Özoran" last="Kürsat">Özoran Kürsat</name></noRegion></country><country name="Turquie"><noRegion><name sortKey="Serpil, Arikan" sort="Serpil, Arikan" uniqKey="Serpil A" first="Arikan" last="Serpil">Arikan Serpil</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F5535857B2197827217518992DAA4B603F3B5298
|texte= Effect of methotrexate on pulmonary involvement in patients with rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |